​

Nuvalent (NUVL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

NUVL Stock Forecast

Nuvalent (NUVL) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $132.74, with a high of $189.00 and a low of $122.85. This represents a 7.53% increase from the last price of $123.45.

$50 $80 $110 $140 $170 $200 High: $189 Avg: $132.74 Low: $122.85 Last Closed Price: $123.45

NUVL Stock Rating

Nuvalent stock's rating consensus is Hold, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (47.06%), 9 Hold (52.94%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 17 0 9 8 Strong Sell Sell Hold Buy Strong Buy

NUVL Price Target Upside V Benchmarks

TypeNameUpside
StockNuvalent7.53%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts121224
Avg Price Target$132.74$132.74$132.79
Last Closing Price$123.45$123.45$123.45
Upside/Downside7.53%7.53%7.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26416---20
May, 26415---19
Apr, 26415---19
Mar, 26414---18
Feb, 26414---18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2026Brad CaninoGuggenheim$124.00$123.250.61%0.45%
Jun 10, 2026David DaiUBS$124.00$123.250.61%0.45%
Jun 09, 2026Truist Financial$124.00$123.250.61%0.45%
Jun 09, 2026Barclays$124.00$123.160.68%0.45%
Jun 09, 2026Robert W. Baird$122.85$123.13-0.23%-0.49%
Jun 09, 2026Stifel Nicolaus$124.00$123.200.65%0.45%
Jun 09, 2026Eva Fortea VerdejoWells Fargo$124.00$122.880.91%0.45%
Jun 09, 2026H.C. Wainwright$124.00$122.850.94%0.45%
Jun 09, 2026Piper Sandler$124.00$122.880.91%0.45%
Jun 09, 2026Wedbush$124.00$122.880.91%0.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026BernsteinOutperformOutperformhold
Jun 10, 2026GuggenheimBuyNeutraldowngrade
Jun 10, 2026UBSBuyNeutraldowngrade
Jun 09, 2026Cowen & Co.BuyHolddowngrade
Jun 09, 2026Raymond JamesOutperformMarket Performdowngrade
Jun 09, 2026H.C. WainwrightBuyNeutraldowngrade
Jun 09, 2026Piper SandlerOverweightNeutraldowngrade
Jun 09, 2026WedbushOutperformNeutraldowngrade
Jun 09, 2026Cantor FitzgeraldOverweightNeutraldowngrade
Jun 02, 2026Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.17$-3.93$-5.85---
Avg Forecast$-2.15$-3.91$-4.51$-4.77$-2.80$-0.70
High Forecast$-2.08$-3.53$-3.96$-2.88$-0.50$-0.70
Low Forecast$-2.21$-4.21$-5.52$-6.59$-5.19$-0.70
Surprise %0.93%0.51%29.71%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$6.25M$36.55M$217.26M$365.44M
High Forecast--$6.25M$37.08M$217.26M$365.44M
Low Forecast--$6.25M$36.01M$217.26M$365.44M
Surprise %------

Net Income Forecast

$-450M $-360M $-270M $-180M $-90M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-126.22M$-260.76M$-425.38M---
Avg Forecast$-126.22M$-224.28M$-312.31M$-330.80M$-237.45M$-40.58M
High Forecast$-120.93M$-205.28M$-230.42M$-167.53M$-28.96M$-40.58M
Low Forecast$-128.56M$-245.39M$-321.42M$-383.72M$-302.26M$-40.58M
Surprise %-16.26%36.21%---

NUVL Forecast FAQ

Is Nuvalent stock a buy?

Nuvalent stock has a consensus rating of Hold, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nuvalent is a neutral investment for most analysts.

What is Nuvalent's price target?

Nuvalent's price target, set by 17 Wall Street analysts, averages $132.74 over the next 12 months. The price target range spans from $122.85 at the low end to $189 at the high end, suggesting a potential 7.53% change from the previous closing price of $123.45.

How does Nuvalent stock forecast compare to its benchmarks?

Nuvalent's stock forecast shows a 7.53% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nuvalent over the past three months?

  • June 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 21.05% Strong Buy, 78.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 21.05% Strong Buy, 78.95% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Nuvalent’s EPS forecast?

Nuvalent's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.77, marking a -18.46% decrease from the reported $-5.85 in 2025. Estimates for the following years are $-2.8 in 2027, and $-0.7 in 2028.

What is Nuvalent’s revenue forecast?

Nuvalent's average annual revenue forecast for its fiscal year ending in December 2026 is $36.55M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $217.26M, and $365.44M for 2028.

What is Nuvalent’s net income forecast?

Nuvalent's net income forecast for the fiscal year ending in December 2026 stands at $-331M, representing a -22.23% decrease from the reported $-425M in 2025. Projections indicate $-237M in 2027, and $-40.576M in 2028.